What Happened?
Vancouver, BC-based Abattis has Appointed Jaouad Fichtali as Chief Technology Officer
About the Company
Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions by supplying and partnering with companies to employ its vertical cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The company also has an extensive pipeline of high-quality products and Intellectual Property for the rapidly expanding botanical drug market. We follow strict Standard Operating Protocols and adhere to the Law`s of Canada and Foreign Jurisdictions. Abattis Bioceuticals Corp. aims to become a leader in the growing, testing, and distribution of medical and adult-use cannabis in North America. Through its network of subsidiaries and partners, the company has developed an innovative GDERS (grow, dry, extract, refine, sell) strategy spanning the entire industry supply chain from seed to sale. These subsidiaries and partners specialize in cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment, and consulting services across the continent. The company follows strict standard operating protocols and adheres to both U.S. and Canadian laws pertaining to the cultivation, testing, and sale of cannabis.
About the Person
Jaouad Fichtali has been the Chief Technology Officer at Abattis Bioceuticals Corp. since November 17, 2014. Dr. Fichtali served as Senior Vice President of Development and Engineering at Bio Architecture Lab, Inc. He led the transition of BAL technology from the lab toward commercialization. He served as Vice President of Technology and Innovation and Vice President of Development at Martek Biosciences, where he built and managed teams from strain development to commercialization including applications development. Along with Martek, he has an established track record in research, development, manufacturing, cost reduction, and commercialization of novel processes and products. Dr. Fichtali earned his PhD from McGill University in Food Science and Agricultural Chemistry and his BS and Masters in Chemical Engineering from Louvain University in Belgium.
Info Source
News
Short Profile